FORMA Therapeutics And Moffitt Cancer Center Alliance
News Sep 24, 2014
FORMA Therapeutics and Moffitt Cancer Center announced a bold, collaborative research initiative and exclusive license option agreement focused on histone deacetylases (HDACs) and epigenetics. This research initiative will emphasize exploring mechanisms of action and differentiation profiles of potential therapeutic drug candidates and will provide critical insights for treating relevant patients with HDAC modulators. Under this agreement, FORMA will pair its ultra-efficient drug discovery team with Moffitt’s world-class clinical and translational scientists in an open-access business framework.
“The integration of members from FORMA and Moffitt into a joint team, combining unique bench-to-bedside experiences, should readily advance our understanding of the biological role of HDACs and their associated substrates. We expect these advances to translate new knowledge into effective therapies.”
“In order to continually advance innovative cancer treatments, interrogating the molecular complexities of immunology and epigenetics is paramount. Working with FORMA’s leading scientists capable of generating potent and specific tools to probe clinical hypotheses has the potential to redefine critical roadmaps that control cancer development,” said Alan F. List, M.D., president and CEO, Moffitt.
“We are privileged to be strategic partners with Moffitt, one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers in the United States. This team validates the molecular signatures in tumors to support the development of personalized therapeutics,” said Steven Tregay, Ph.D., president and CEO, FORMA Therapeutics. “Our collaboration with Moffitt enables us to efficiently match our drugs to the right patients and realize a precision medicine approach to cancer drug development.”
In addition to conducting joint research studies, the framework for this newly-minted epigenetics alliance includes explorations into novel targets and other emerging epigenetic mechanisms through “Moffitt Innovative Studies.” This strategic directive provides Moffitt researchers with the opportunity to identify exciting new areas in the epigenetics arena managed via an internal peer-review process. Together, these two activities will enhance the long-term success of this partnership.
This partnership structure will provide access to in vitro and in vivo biological systems, as well as anonymized patient samples for functional profiling. The team will explore identification and characterization of non-histone HDAC substrates to fully understand the role of selective HDAC inhibitors on immune and cancer cell function and to evaluate bioactivity in applicable disease models.
“Our relationship with Moffitt provides the opportunity to significantly accelerate understanding of the clinical application for highly selective histone deacetylase modulators, enzymes involved in histone acetylation and transcriptional regulation, as well as other key epigenetic and immune control factors. This unique opportunity to probe the pathophysiological contributions of target-selective compounds across related molecular pathways in a disease-relevant setting will guide our creation of breakthrough drugs,” said Kenneth W. Bair, Ph.D., chief scientific officer and head of Research and Development, FORMA Therapeutics.
The alliance will be co-led at Moffitt by Ed Seto, Ph.D., senior member, Department of Molecular Oncology; and Eduardo M. Sotomayor, M.D., Susan and John Sykes Endowed Chair in Hematologic Malignancies, senior member and chair, Department of Malignant Hematology.
“The integration of members from FORMA and Moffitt into a joint team, combining unique bench-to-bedside experiences, should readily advance our understanding of the biological role of HDACs and their associated substrates. We expect these advances to translate new knowledge into effective therapies,” said Seto.
“It is extremely rewarding to partner with the FORMA Therapeutics team and collectively influence the discovery and translational development of future therapeutic medicines. FORMA’s selection of Moffitt for this expansive partnership was based on our assemblage of renowned clinical researchers with broad knowledge in HDAC biology and proven clinical research expertise at the forefront of the oncology-immune-epigenetic axis,” said Sotomayor.
As part of this agreement, a collaborative consortium on epigenetics will consist of:
- FORMA Therapeutics Inc.
- Moffitt Cancer Center
- Co-chair: Ed Seto, Ph.D., senior member, Department of Molecular Oncology
- Co-chair: Eduardo M. Sotomayor, M.D., senior member and chair, Department of Malignant Hematology
- James J. Mulé, Ph.D., senior member, associate center director, Translational Research, Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, director of Cell-Based Therapies
- Claudio Anasetti, M.D., senior member and chair, Department of Blood & Marrow Transplantation
- Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence, senior member, Department of Cutaneous Oncology
- P.K. Epling-Burnette, PharmD, Ph.D., senior member, Immunology Program
- Brian Betts, M.D., assistant member, Department of Blood & Marrow Transplantation
- Alejandro Villagra, Ph.D., research scientist, Immunology Program
“The internal scientific ecosystem Moffitt has built integrates a broad array of disciplines including immune regulation, epigenetic control, tumor metastasis and translational genomics. Further, Moffitt’s organizational structure as a multidisciplinary team of basic scientists, physician-scientists, clinicians and hematopathologists, operating within a functional matrix team to explore HDAC biology, drove FORMA’s interest in a partnership. We are pleased to expand FORMA’s community of external scientists to include Moffitt as a cornerstone network member,” said Rob Sarisky, Ph.D., chief business officer, FORMA Therapeutics.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.